← Leaderboards
Kyuson Yun
Methodist Hospital Research Institute
$4,256,934
Attributed
$6,781,838
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,781,838 · 5
By mechanism
R01$5,190,139 · 2
R21$831,492 · 2
R56$760,207 · 1
Top collaborators
- David Gallup4 shared
- Naoto T Ueno4 shared
- Alireza Faridar1 shared
- Juan B Toledo Atucha1 shared
Most similar at Methodist Hospital Research Institute
Same institution · by research overlap
- Alireza Faridar$1,227,361
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMouse ModelReportingTumorMalignant NeoplasmsTissuesSolid NeoplasmImmunotherapyChemotherapyCancer PatientInsightBrain NeoplasmsMalignant Neoplasm Of BrainPhenotypeSignal TransductionRecurrenceSerumCharacteristicsImmuneReagentMicrogliaIn VivoBone MarrowAstrocytes
Grant awards (14)
Validation of a novel 3D culture platform for TNBC treatment selection$1,198,662
R01 · FY2025 · CA · contact PI
S100A4 mediated immune suppression in GBM$394,788
R01 · FY2025 · NS · contact PI
Multi-omic integrative analysis of shared and distinct inflammation networks across neurodegenerative disorders$760,207
R56 · FY2024 · AG
Validation of a novel 3D culture platform for TNBC treatment selection$583,104
R01 · FY2024 · CA · contact PI
S100A4 mediated immune suppression in GBM$425,493
R01 · FY2024 · NS · contact PI
Validation of a novel 3D culture platform for TNBC treatment selection$601,157
R01 · FY2023 · CA · contact PI
S100A4 mediated immune suppression in GBM$438,652
R01 · FY2023 · NS · contact PI
Validation of a novel 3D culture platform for TNBC treatment selection$644,226
R01 · FY2022 · CA · contact PI
S100A4 mediated immune suppression in GBM$438,652
R01 · FY2022 · NS · contact PI
S100A4 mediated immune suppression in GBM$465,405
R01 · FY2021 · NS · contact PI
Testing the Cancer Stem Cell Hypothesis: Role of CD133+ Cells as Tumor Stem Cells$227,063
R21 · FY2008 · NS · contact PI
MPS VII CNS Gene Therapy Using Neuronal Stem Cells$215,635
R21 · FY2007 · NS · contact PI
Testing the Cancer Stem Cell Hypothesis: Role of CD133+ Cells as Tumor Stem Cells$189,219
R21 · FY2007 · NS · contact PI
MPS VII CNS Gene Therapy Using Neuronal Stem Cells$199,575
R21 · FY2006 · NS · contact PI